



FGFR2 gene

fibroblast growth factor receptor 2

Normal Function

The *FGFR2* gene provides instructions for making a protein called fibroblast growth factor receptor 2. This protein is one of four fibroblast growth factor receptors, which are related proteins that are involved in important processes such as cell division, regulation of cell growth and maturation, formation of blood vessels, wound healing, and embryonic development.

The FGFR2 protein spans the cell membrane, so that one end of the protein remains inside the cell and the other end projects from the outer surface of the cell. This positioning allows the FGFR2 protein to interact with specific growth factors outside the cell and to receive signals that help the cell respond to its environment. When growth factors attach to the FGFR2 protein, the receptor triggers a cascade of chemical reactions inside the cell that instruct the cell to undergo certain changes, such as maturing to take on specialized functions. The FGFR2 protein plays an important role in bone growth, particularly during embryonic development. For example, this protein signals certain immature cells in the developing embryo to become bone cells in the head, hands, feet, and other tissues.

There are several slightly different versions (isoforms) of the FGFR2 protein. Specific patterns of these isoforms are found in the body's tissues, and these patterns may change throughout growth and development.

Health Conditions Related to Genetic Changes

Apert syndrome

At least seven mutations in the *FGFR2* gene have been found to cause Apert syndrome, a condition that causes premature closure of the bones of the skull (craniosynostosis), leading to a misshapen head and distinctive facial features, and abnormalities of the fingers and toes. Nearly all cases of Apert syndrome are caused by one of two mutations in the *FGFR2* gene. These mutations change single protein building blocks (amino acids) in the FGFR2 protein, which alters the protein's 3-dimensional structure. One mutation replaces the amino acid serine with the amino acid tryptophan at protein position 252 (written as Ser252Trp). The other mutation replaces the amino acid proline with the amino acid arginine at position 253 (written as Pro253Arg). The altered FGFR2 protein appears to cause stronger signaling, which promotes the premature fusion of bones in the skull, hands, and feet.

Beare-Stevenson cutis gyrata syndrome

At least three mutations in the *FGFR2* gene have been found to cause Beare-Stevenson cutis gyrata syndrome, a condition that causes craniosynostosis, leading to a misshapen head and distinctive facial features, and a skin abnormality called cutis gyrata. The most common mutation replaces the amino acid tyrosine with the amino acid cysteine at position 375 in the protein (written as Tyr375Cys). The *FGFR2* gene mutations that cause Beare-Stevenson cutis gyrata syndrome appear to overactivate signaling by the FGFR2 protein, which promotes the premature fusion of bones in the skull.

breast cancer

cholangiocarcinoma

Crouzon syndrome

At least 40 mutations in the *FGFR2* gene can cause Crouzon syndrome, a condition that causes craniosynostosis, leading to a misshapen head and distinctive facial features. Most of the mutations that cause Crouzon syndrome change single DNA building blocks (nucleotides) in the *FGFR2* gene. Insertions and deletions of a small number of nucleotides are also known to cause the disorder. These mutations in *FGFR2* appear to overactivate signaling by the FGFR2 protein, which promotes premature fusion of bones in the skull.

epidermal nevus

Jackson-Weiss syndrome

At least six mutations in the *FGFR2* gene have been found to cause Jackson-Weiss syndrome. This condition causes craniosynostosis, leading to a misshapen head and distinctive facial features, and foot abnormalities. Each of the mutations changes a single amino acid in a region of the FGFR2 protein known as the IgIII domain, which is critical for receiving signals and interacting with growth factors. The mutations appear to overactivate signaling by the FGFR2 protein, which promotes premature fusion of skull bones and affects the development of bones in the feet.

lacrimo-auriculo-dento-digital syndrome

At least two mutations in the *FGFR2* gene have been found to cause lacrimo-auriculo-dento-digital (LADD) syndrome. These mutations reduce the FGFR2 receptor protein's ability to trigger chemical reactions within cells when it binds to its growth factor. A mutation that occurs in some people with LADD syndrome replaces the amino acid alanine with the amino acid threonine at position 628 in the FGFR2 receptor protein (written as Ala628Thr or A628T).

The main features of LADD syndrome are abnormal tear production, malformed ears with hearing loss, decreased saliva production, small teeth, and hand deformities. The *FGFR2* gene mutations that cause LADD syndrome reduce the function of the receptor protein, resulting in a decrease in cell signaling. These defects in cell signaling disrupt cell maturation and development, which results in abnormal formation of glands in the eyes and mouth, the ears, and the skeleton in people with LADD syndrome.

Pfeiffer syndrome

More than 25 mutations in the *FGFR2* gene can cause Pfeiffer syndrome, a condition that causes craniosynostosis, leading to a misshapen head and distinctive facial features, and hand and foot abnormalities. Several of the mutations that cause this condition change the number of cysteine amino acids in a critical region of the FGFR2 protein known as the IgIII domain. The remaining mutations affect amino acids other than cysteine or result in an FGFR2 protein that is missing one or more amino acids. These mutations appear to overactivate signaling by the FGFR2 protein, which promotes premature fusion of skull bones and affects the development of bones in the hands and feet.

prostate cancer

cancers


Alterations in the activity (expression) of the *FGFR2* gene are associated with certain cancers. The altered gene expression may enhance several cancer-related events such as cell division (proliferation), cell movement, and the development of new blood vessels that nourish a growing tumor.

The *FGFR2* gene is abnormally active (overexpressed) in certain types of stomach cancers, and this amplification is associated with a poor disease outcome. Abnormal expression of the *FGFR2* gene is also found in patients with prostate cancer. A shift in the expression of two specific FGFR2 isoforms, IIIb and IIIc, appears to correlate with prostate cancer progression. This change in expression is complex, however, and varies depending on the type of prostate tumor. More advanced tumors may show an increase in the IIIb isoform, while other prostate tumors show a decrease in IIIb but an increase in IIIc. Altered *FGFR2* gene expression is also associated with ovarian, breast, cervical, pancreatic, and head and neck cancers.

Chromosomal Location

Cytogenetic Location: 10q26.13, which is the long (q) arm of chromosome 10 at position 26.13

Molecular Location: base pairs 121,478,330 to 121,598,656 on chromosome 10 (Homo sapiens Annotation Release 108, GRCh38.p7) (NCBI)



Credit: Genome Decoration Page/NCBI

Other Names for This Gene

- bacteria-expressed kinase
- BEK
- BEK fibroblast growth factor receptor
- BEK protein tyrosine kinase
- BFR-1
- CD332
- CEK3
- CFD1
- ECT1
- FGF receptor
- FGFR2_HUMAN
- K-SAM
- keratinocyte growth factor receptor
- KGFR
- protein tyrosine kinase, receptor like 14
- TK14
- TK25
- tyrosylprotein kinase

Additional Information & Resources

Educational Resources

- Eureka Bioscience Collection: Fibroblast Growth Factors (FGFs) and FGF Receptors
<https://www.ncbi.nlm.nih.gov/books/NBK6330/>

GeneReviews

- FGFR-Related Craniosynostosis Syndromes
<https://www.ncbi.nlm.nih.gov/books/NBK1455>

Scientific Articles on PubMed

- PubMed
<https://www.ncbi.nlm.nih.gov/pubmed?term=%28FGFR2%5BTIAB%5D%29+AND+%28%28Genes%5BMH%5D%29+OR+%28Genetic+Phenomena%5BMH%5D%29%29+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last+720+days%22%5Bdp%5D>

OMIM

- FIBROBLAST GROWTH FACTOR RECEPTOR 2
<http://omim.org/entry/176943>

Research Resources

- Atlas of Genetics and Cytogenetics in Oncology and Haematology
<http://atlasgeneticsoncology.org/Genes/FGFR2ID40570ch10q26.html>
- ClinVar
<https://www.ncbi.nlm.nih.gov/clinvar?term=FGFR2%5Bgene%5D>
- HGNC Gene Family: CD molecules
<http://www.genenames.org/cgi-bin/genefamilies/set/471>
- HGNC Gene Family: I-set domain containing
<http://www.genenames.org/cgi-bin/genefamilies/set/593>
- HGNC Gene Family: Receptor Tyrosine Kinases
<http://www.genenames.org/cgi-bin/genefamilies/set/321>
- HGNC Gene Symbol Report
http://www.genenames.org/cgi-bin/gene_symbol_report?q=data/hgnc_data.php&hgnc_id=3689
- NCBI Gene
<https://www.ncbi.nlm.nih.gov/gene/2263>
- UniProt
<http://www.uniprot.org/uniprot/P21802>

Sources for This Summary

- Carinci F, Pezzetti F, Locci P, Becchetti E, Carls F, Avantaggiato A, Becchetti A, Carinci P, Baroni T, Bodo M. Apert and Crouzon syndromes: clinical findings, genes and extracellular matrix. *J Craniofac Surg*. 2005 May;16(3):361-8. Review.
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/15915098>
- Chen L, Deng CX. Roles of FGF signaling in skeletal development and human genetic diseases. *Front Biosci*. 2005 May 1;10:1961-76. Review.
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/15769677>
- Chokdeemboon C, Mahatumarat C, Rojvachiranonda N, Tongkobpetch S, Suphapeetiporn K, Shotelersuk V. FGFR1 and FGFR2 mutations in Pfeiffer syndrome. *J Craniofac Surg*. 2013 Jan; 24(1):150-2. doi: 10.1097/SCS.0b013e3182646454.
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/23348274>
- Cornejo-Roldan LR, Roessler E, Muenke M. Analysis of the mutational spectrum of the FGFR2 gene in Pfeiffer syndrome. *Hum Genet*. 1999 May;104(5):425-31.
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/10394936>
- Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. *Cytokine Growth Factor Rev*. 2005 Apr;16(2):139-49. Epub 2005 Feb 1. Review.
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/15863030>
- Ibrahimi OA, Chiu ES, McCarthy JG, Mohammadi M. Understanding the molecular basis of Apert syndrome. *Plast Reconstr Surg*. 2005 Jan;115(1):264-70. Review.
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/15622262>
- Ibrahimi OA, Zhang F, Eliseenkova AV, Linhardt RJ, Mohammadi M. Proline to arginine mutations in FGF receptors 1 and 3 result in Pfeiffer and Muenke craniosynostosis syndromes through enhancement of FGF binding affinity. *Hum Mol Genet*. 2004 Jan 1;13(1):69-78. Epub 2003 Nov 12.
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/14613973>
- Lajeunie E, Heuertz S, El Ghouzzi V, Martinovic J, Renier D, Le Merrer M, Bonaventure J. Mutation screening in patients with syndromic craniosynostoses indicates that a limited number of recurrent FGFR2 mutations accounts for severe forms of Pfeiffer syndrome. *Eur J Hum Genet*. 2006 Mar; 14(3):289-98.
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/16418739>
- Lew ED, Bae JH, Rohmann E, Wollnik B, Schlessinger J. Structural basis for reduced FGFR2 activity in LADD syndrome: Implications for FGFR autoinhibition and activation. *Proc Natl Acad Sci U S A*. 2007 Dec 11;104(50):19802-7. Epub 2007 Dec 3.
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/18056630>
Free article on PubMed Central: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2148379/>
- Naimi B, Latil A, Fournier G, Mangin P, Cussenot O, Berthon P. Down-regulation of (IIIb) and (IIIc) isoforms of fibroblast growth factor receptor 2 (FGFR2) is associated with malignant progression in human prostate. *Prostate*. 2002 Aug 1;52(3):245-52.
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/12111699>
- Rohmann E, Brunner HG, Kayserili H, Uyguner O, Nürnberg G, Lew ED, Dobbie A, Eswarakumar VP, Uzumcu A, Ulubil-Emeroglu M, Leroy JG, Li Y, Becker C, Lehnerdt K, Cremers CW, Yüksel-Apak M, Nürnberg P, Kubisch C, Schlessinger J, van Bokhoven H, Wollnik B. Mutations in different components of FGF signaling in LADD syndrome. *Nat Genet*. 2006 Apr;38(4):414-7. Epub 2006 Feb 26. Erratum in: *Nat Genet*. 2006 Apr;38(4):495. Kubisch, Chriütian [corrected to Kubisch, Christian].
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/16501574>

- Shams I, Rohmann E, Eswarakumar VP, Lew ED, Yuzawa S, Wollnik B, Schlessinger J, Lax I. Lacrimo-auriculo-dento-digital syndrome is caused by reduced activity of the fibroblast growth factor 10 (FGF10)-FGF receptor 2 signaling pathway. *Mol Cell Biol*. 2007 Oct;27(19):6903-12. Epub 2007 Aug 6.
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/17682060>
Free article on PubMed Central: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2099236/>
- Shin EY, Lee BH, Yang JH, Shin KS, Lee GK, Yun HY, Song YJ, Park SC, Kim EG. Up-regulation and co-expression of fibroblast growth factor receptors in human gastric cancer. *J Cancer Res Clin Oncol*. 2000 Sep;126(9):519-28.
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/11003564>
- Wilkie AO, Patey SJ, Kan SH, van den Ouweland AM, Hamel BC. FGFs, their receptors, and human limb malformations: clinical and molecular correlations. *Am J Med Genet*. 2002 Oct 15; 112(3):266-78. Review.
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/12357470>
- Wilkie AO. Bad bones, absent smell, selfish testes: the pleiotropic consequences of human FGF receptor mutations. *Cytokine Growth Factor Rev*. 2005 Apr;16(2):187-203. Epub 2005 Apr 1. Review.
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/15863034>

Reprinted from Genetics Home Reference:
<https://ghr.nlm.nih.gov/gene/FGFR2>

Reviewed: June 2013

Published: March 21, 2017

Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
National Institutes of Health
Department of Health & Human Services